COMP <GO>
MIRM vs MRK // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Mirum Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: MIRM 4
— MRK 10
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: MRK
LAST: $85.00 (-1.61%) • MKT CAP: $5.61B
options-implied-move
6.90%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
options-implied-move
6.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MIRM VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MIRM | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.90% | 20.70% | -24.60 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.98% | 3.42% | -2.44 | MRK | /fcf-yield <GO> |
| Operating Margin | -4.20% | 34.30% | -38.50 | MRK | /operating-margins <GO> |
| Net Profit Margin | -4.50% | 28.10% | -32.60 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 54.70% | 1.30% | +53.40 | MIRM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.29 | 5.19 | +1.10 | MIRM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | MIRM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.90% | 6.60% | +0.30 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.7 | 56.9 | -8.17 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.92 | +0.07 | MIRM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 18.4x | +13.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.61B | $361.02B | -$355.41B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MIRM REV | MRK REV | MIRM GROSS % | MRK GROSS % | MIRM FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $521.3M | $65.01B | 44.0% | 74.8% | $54.9M | $12.36B |
| FY 2024 | $336.9M | $64.17B | 44.0% | 76.3% | $9.3M | $18.10B |
| FY 2023 | $186.4M | $60.12B | 44.0% | 44.0% | -$79.3M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MIRM // BETA 0.99
MRK // BETA 0.92